Orchestra BioMed Holdings, Inc. (OBIO)
After hours:
- Zacks
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?
The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024. Details of the presentation are below. Format: Fireside Chat Date: Wed
